Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report

BACKGROUND: This article summarizes the 2012 European Renal Association-European Dialysis and Transplant Association Registry Annual Report (available at www.era-edta-reg.org) with a specific focus on older patients (defined as ≥65 years). METHODS: Data provided by 45 national or regional renal registries in 30 countries in Europe and bordering the Mediterranean Sea were used. Individual patient level data were received from 31 renal registries, whereas 14 renal registries contributed data in an aggregated form. The incidence, prevalence and survival probabilities of patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT) and renal transplantation rates for 2012 are presented. RESULTS: In 2012, the overall unadjusted incidence rate of patients with ESRD receiving RRT was 109.6 per million population (pmp) (n = 69 035), ranging from 219.9 pmp in Portugal to 24.2 pmp in Montenegro. The proportion of incident patients ≥75 years varied from 15 to 44% between countries. The overall unadjusted prevalence on 31 December 2012 was 716.7 pmp (n = 451 270), ranging from 1670.2 pmp in Portugal to 146.7 pmp in the Ukraine. The proportion of prevalent patients ≥75 years varied from 11 to 32% between countries. The overall renal transplantation rate in 2012 was 28.3 pmp (n = 15 673), with the highest rate seen in the Spanish region of Catalonia. The proportion of patients ≥65 years receiving a transplant ranged from 0 to 35%. Five-year adjusted survival for all RRT patients was 59.7% (95% confidence interval, CI: 59.3-60.0) which fell to 39.3% (95% CI: 38.7-39.9) in patients 65-74 years and 21.3% (95% CI: 20.8-21.9) in patients ≥75 years

Current Status of Renal Replacement Therapies in Turkey: Turkish Society of Nephrology Registry 2015 Summary Report

OBJECTIVE: The Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis and transplantation on an annual basis. Registry reports are printed every year as a booklet and this is the 26th year of registry reports. The registry is in close collaboration with international registries

European Best Practice Guideline on Kidney Donor and Recipient Evaluation and Perioperative Care

Caring for kidney transplant recipients (KTRs) requires specialized knowledge in areas as varied as nephrology, immunology, pharmacology, endocrinology, infectious disease, and cardiology. In this context of increasing complexity coupled with an exponential growth in medical literature, clinical practice guidelines (CPGs) aim at helping clini-cians and other caregivers to deliver evidence-based medicine and thereby, to improve patient outcomes. Furthermore, guidelines also help to expose gaps in our knowledge, and thereby suggest areas where additional research is needed

Current Status of Renal Replacement Therapies in Turkey: Summary of Turkish Society of Nephrology Registry 2016 Report

OBJECTIVE: The Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis and transplantation on an annual basis. Registry reports are printed every year as a booklet and this is the 27th year of the registry reports. The registry is in close collaboration with international registries

Current Status of Renal Replacement Therapy in Turkey: A Summary of 2020 Turkish Society of Nephrology Registry Report

© 2022 Turkish Society of Nephrology. All rights reserved.Objective: Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis, and transplantation annually. Registry reports are printed every year as a booklet, and this is the 31st year of registry reports. The registry is in close collaboration with international registries. Methods: In this paper, we summarized data from the 2020 registry report; additionally, we also provided yearly trends of managing end-stage kidney disease. Results: The number of patients on renal replacement therapy decreases; at the end of 2020, 83 350 patients were on renal replacement therapy. The prevalence and incidence of end-stage renal disease were 996.8 and 138.7 per million population, respectively. Diabetes was the most common cause of end-stage renal disease. Hemodialysis (72.7%) was the most common type of treatment modality, followed by transplantation (23.3%) and peritoneal dialysis (4.06%). Conclusion: End-stage kidney disease is a critical and growing health problem for our country. The renal registry of the Turkish society of nephrology is one of the leading tools for providing current and sound data on this public health problem

Ciprofloxacin Does Not Exert Nephrotoxicity in Rats

Ciprofloxacin, a member of the fluoroquinolone class, is an antibiotic used as a treatment for infections including the Anthrax bacteria. Studies concerning the safety and efficacy of ciprofloxacin have been controversial with respect to nephrotoxicity. Using rats orally treated with ciprofloxacin (400mg/kg/d), the effects of this drug were analyzed measuring several indications of nephrotoxicity: -NAG, creatinine, blood urea nitrogen, and sodium and potassium levels in blood samples. Additionally, histological analyses were performed. -NAG values, a measure of early renal damage, were significantly increased after 4 and 7 days of treatment (p = 0.001 and p = 0.004, respectively) compared with control rats. However, 7 days post-treatment, -NAG values decreased to control levels indicative that adaptive responses were induced to prevent nephrotoxicity. These results indicate that ciprofloxacin in doses comparable to those commonly prescribed does not induce nephrotoxicity. Altogether, they further support the idea that ciprofloxacin can be safely use